Alethiomics is a biotech company harnessing the power of single-cell multi-omic technology to discover & develop treatment for blood cancer.
Alethiomics has raised $8.0M in total funding. The most recent round was Seed. The last funding was announced in December 2021.
Alethiomics's investors include Oxford Science Enterprises.
Alethiomics is headquartered in Headington, United Kingdom.
Alethiomics is a biotech company harnessing the power of single-cell multi-omic technology to discover & develop treatment for blood cancer.
Alethiomics is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Alethiomics — Funding & Investors." VCBacked, December 15, 2021, https://www.vcbacked.co/company/alethiomics. Accessed August 15, 2026.
VCBacked. (2021). Alethiomics — Funding & Investors. Retrieved August 15, 2026, from https://www.vcbacked.co/company/alethiomics
{{cite web |title=Alethiomics — Funding & Investors |url=https://www.vcbacked.co/company/alethiomics |website=VCBacked |access-date=August 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated